(Reuters) - Adding Johnson & Johnson's advanced prostate
cancer drug, Zytiga, to hormone therapy before surgery has been shown for the
first time to eradicate tumors in some men with high-risk forms of the disease.
The mid-stage trial found that six months of treatment with the combination
therapy completely or nearly eliminated the cancer in a third of patients, all
of whom had localized, aggressive cancer. ...
(Reuters) - Adding Johnson & Johnson's advanced prostate
cancer drug, Zytiga, to hormone therapy before surgery has been shown for the
first time to eradicate tumors in some men with high-risk forms of the disease.
The mid-stage trial found that six months of treatment with the combination
therapy completely or nearly eliminated the cancer in a third of patients, all
of whom had localized, aggressive cancer. ...
